ArticlePharmaceutical biology2021
Bioadhesive hydrogel comprising bilirubin/β-cyclodextrin inclusion complexes promote diabetic wound healing.
Article in Pharmaceutical biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 31 citations in OpenAlex.
- Engineered novel dually cross-linked hydrogel system embedded with Apigenin-cyclodextrin complex for surgical wound healing.Scientific reports · 2026Article
- A review on β-cyclodextrin-based self-healable supramolecular systems: mechanisms and biomedical applications.RSC advances · 2026Review
- RCN1 downregulation-driven endoplasmic reticulum stress impairs endothelial function and diabetic foot ulcer healing.Cellular and molecular life sciences : CMLS · 2025Article
- Exo-hydrogel therapy: a revolutionary approach to managing diabetic complications.Journal of nanobiotechnology · 2025Review
- Cyclodextrins as multifunctional tools for advanced biomaterials in tissue repair and regeneration.Bioactive materials · 2025Review
- Formulation of Caffeine-Hydroxypropyl-β-Cyclodextrin Complex in Hydrogel for Skin Treatment.Gels (Basel, Switzerland) · 2025Article
- Enhancing oocyte in vitro maturation and quality by melatonin/bilirubin cationic nanoparticles: A promising strategy for assisted reproduction techniques.International journal of pharmaceutics: X · 2024Article
- Incorporation of Resveratrol-Hydroxypropyl-β-Cyclodextrin Complexes into Hydrogel Formulation for Wound Treatment.Gels (Basel, Switzerland) · 2024Article
- Fabrication and evaluation of ribavirin-loaded electrospun nanofibers as an antimicrobial wound dressing.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2024Article
- Review
- Toward nanotechnology-enabled application of bilirubin in the treatment and diagnosis of various civilization diseases.Materials today. Bio · 2023Review
- Biochemical aspects of effects of mesenchymal stem cell treatment in chronic wounds progressive healing.Cell and tissue banking · 2023Article
- Current and future outlook of loaded components in hydrogel composites for the treatment of chronic diabetic ulcers.Frontiers in bioengineering and biotechnology · 2023Review
- Bilirubin as a Therapeutic Molecule: Challenges and Opportunities.Antioxidants (Basel, Switzerland) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
contextChronic non-healing diabetic wound therapy is an important clinical challenge. Manipulating the release of bioactive factors from an adhesive hydrogel is an effective approach to repair chronic wounds. As an endogenous antioxidant, bilirubin (BR) has been shown to promote wound healing. Nonetheless, its application is limited by its low water solubility and oxidative degradation.
objectiveThis study developed a bilirubin-based formulation for diabetic wound healing. MATERIALS AND
methodsBilirubin was incorporated into β-CD-based inclusion complex (BR/β-CD) which was then loaded into a bioadhesive hydrogel matrix (BR/β-CD/SGP). Scratch wound assays were performed to examine the
resultsCompared to untreated (18.7%) and BR (55.2%) groups, wound closure was more pronounced (65.0%) in BR/β-CD/SGP group. In diabetic rats, the wound length in BR/β-CD/SGP group was smaller throughout the experimental period than untreated groups. Moreover, BR/β-CD/SGP decreased TNF-α levels to 7.7% on day 3, and elevated collagen deposition and VEGF expression to 11.9- and 8.2-fold on day 14. The therapeutic effects of BR/β-CD/SGP were much better than those of the BR group. Similar observations were made in the non-diabetic model. DISCUSSION AND
conclusionBR/β-CD/SGP promotes wound healing and tissue remodelling in both diabetic and non-diabetic rats, indicating an ideal wound-dressing agent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.